ClinicalTrials.gov
public full text
Public Domain
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study#254385
- External Body Pressure in Heart Failure With Preserved Ejection Fraction#994999
- Skeletal Muscle Dysfunction in Heart Failure with Preserved Ejection Fraction / Beatrice Vahle ; Gutachter: Volker Adams, Martin Bahls#669405
- Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction#624958
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial#1103703
Record · ID 1382010
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive